Log in to search using one of your social media accounts:

 

MS Drug Tysabri (Natalizumab) Poses Hard Choices for Women Wanting Children

THURSDAY, Feb. 8, 2018 -- A powerful multiple sclerosis drug presents women with a tough dilemma if they would like to have children, a pair of new studies suggests. Those who take Tysabri (natalizumab) to manage their MS are more likely to suffer...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news

Related Links:

Acute appendicitis is the most common surgical emergency and becomes serious when it perforates. The principal presenting complaint of patients with acute appendicitis is abdominal pain. The diagnosis may be missed in patients with neurological disorders- in this case multiple sclerosis (MS) and quadriplegia-who do not complain of pain. There are limited research and practice guidelines for patients with chronic neurodegenerative disorders with acute abdomen.
Source: Journal of the American Medical Directors Association - Category: Health Management Authors: Tags: Case Report Source Type: research
Cladribine is the first disease modifying treatment (DMT) for relapsing remitting multiple sclerosis (RRMS) that progressed straight to a positive final recommendation in the NICE appraisal process. The final recommendations were published in December 2017.1 An agreement between NHS England and Merck, the manufacturer of cladribine (Mavenclad), will allow MS patients who are suffering from highly active or rapidly evolving RRMS to access the drug. Here, the authors discuss the clinical and economic considerations for cladribine usage.
Source: Progress in Neurology and Psychiatry - Category: Neurology Authors: Tags: Comment Source Type: research
Increasing evidence links the microbiome's composition with several psychiatric and neurological diseases, including autism, schizophrenia, attention deficit hyperactivity disorder, Parkinson's disease, Alzheimer's disease and multiple sclerosis – Mark Greener investigates.
Source: Progress in Neurology and Psychiatry - Category: Neurology Authors: Tags: News review Source Type: research
The cystine/glutamate antiporter (xc-) has been implicated in several neurological disorders and, specifically, in multiple sclerosis (MS) as a mediator of glutamate excitotoxicity and proinflammatory immune r...
Source: Journal of Neuroinflammation - Category: Neurology Authors: Tags: Research Source Type: research
Benign multiple sclerosis (BMS) is a controversial term that has been used for MS patients with minimal disability decades after disease onset. Herein, we evaluated disease status after 20  years in a Western Australian cohort defined as BMS based on an Expanded Disability Status Scale (EDSS) score ≤ 3.0 at 10 years from onset.
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Source Type: research
This article summarises its dosing and monitoring requirements, efficacy in the CLARITY trial and place in therapy.
Source: Prescriber - Category: Primary Care Authors: Tags: New Product Source Type: research
Publication date: Available online 22 February 2018 Source:Multiple Sclerosis and Related Disorders Author(s): Franziska Di Pauli, Markus Reindl, Thomas Berger Acquired demyelinating CNS syndromes include a broad spectrum of clinical phenotypes and different entities can overlap. Therefore, differential diagnosis is still challenging. A humoral immune reaction against myelin oligodendrocyte glycoprotein (MOG) is present in a subgroup of these patients, particularly in children. Anti-MOG antibodies indicate a non-multiple sclerosis disease course. Indeed, early publications have suggested that anti-MOG antibodies argue for...
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
No abstract available
Source: Journal of Neuro-Ophthalmology - Category: Opthalmology Tags: Disease of the Year: Multiple Sclerosis Source Type: research
Conclusions: There have been great advances in therapeutic research in MS. However, the stratification of patients according to their prognosis and predictive outcomes in response to treatment is still in its infancy. The many facets of MS make it difficult to piece all the data together into one cohesive conclusion for the individual patient. The visual system, with our ability to assess both structure and function, offers a promising opportunity to study both pathophysiologic mechanisms and novel therapies.
Source: Journal of Neuro-Ophthalmology - Category: Opthalmology Tags: Disease of the Year: Multiple Sclerosis Source Type: research
Conclusions: This review highlights our current knowledge of the underlying disease mechanisms in MS, explores the inflammatory and neurodegenerative consequences of tissue damage, and examines physiologic factors that contribute to bioenergetic homeostasis within the CNS of affected patients.
Source: Journal of Neuro-Ophthalmology - Category: Opthalmology Tags: Disease of the Year: Multiple Sclerosis Source Type: research
More News: Children | General Medicine | Multiple Sclerosis | Study | Tysabri | Women